901 East 86th Street
Indianapolis, Indiana 46240
317-844-5500    |    866-657-6890
Restor

Make An Appointment

If you would like to schedule an appointment, please complete the fields below and someone from our office will contact you to confirm your appointment details. Using this form just takes a moment.

Crystalens

LASIK

Discount & Coupons

Patient Financing




Restor

The Acrysof® Restor® IOL
How does the AcrySof® ReSTOR® Multifocal IOL work?

When we perform various activities throughout the day that require vision such as reading the newspaper or driving a car our eyes are constantly changing focus at various distances. When changing focus at varying distances our eyes need to accommodate. You may already understand this but as you get older this ability to accommodate gets more difficult. Typically people over 40 start to require reading glasses or bifocal lenses. Now that the AcrySof® ReSTOR® Multifocal IOL is available at Eye Physicians of Long Beach our patients can see better at a multitude of distances.

The Acrysof® Restor® IOL was one of the very first premium lens implants that achieved a high level of success. Many patients speak very highly of this implant and many patients that wore glasses for year so not wear them anymore with the exception of a few instances. The FDA data indicates that 80% of patients were spectacle-free after cataract surgery with this lens implant. Patients often describe that they can see more clear and with more vibrance.


Who is a Restor candidate?

  • Any patient who has a normal eye exam and is dependent on reading glasses or bifocals may be a candidate. it is not necessary to need cataract surgery to qualify for the ReSTOR lens, just a desire to restore eyesight at a range of distances without corrective eyewear.

There are no known contraindications. However, based on the FDA clinical trials, Alcon, the lens manufacturer, has indicated the following types of patients possibly should not have the AcrySof ReSTOR Apodized Diffractive IOL:

  • People with unrealistic expectations
  • People with psychiatric disorders
  • People with a history of glare in night vision

FDA approval date:
March 21, 2005. It has been approved for use in Europe since April 4, 2003.